文献速递其他结缔组织病系统性红斑狼疮

炎症性风湿病患者重组带状疱疹疫苗:免疫抑制下的效力、长期保护与安全性

Recombinant zoster vaccine in patients with inflammatory rheumatic diseases: efficacy, long-term protection and safety under immunosuppression.
PubMed 文献 · RMD Open · 2026-05-18

综述总结重组带状疱疹疫苗(RZV)在炎症性风湿病(IRD)患者中的效力、长期保护与安全性证据。随机对照试验显示短期 flare 风险非劣于安慰剂;真实世界数据显示接种后 HZ 复发约减少 95%;药物警戒分析 920 例自身免疫病患者中 flare 发生率 8.5%,报告 OR 三倍升高,尤见于系统性红斑狼疮。EULAR、ACR、ACIP/CDC 等推荐高风险 IRD 成人接种两剂 RZV。

要点

  • RZV 在稳定免疫抑制的 IRD 患者中短期 flare 风险非劣于安慰剂。
  • 真实世界数据示接种后 HZ 复发约减少 95%,严重疫苗相关事件罕见。
  • 药物警戒分析示自身免疫病患者 post-RZV flare 报告 OR 三倍升高,需短期监测。

核心结论

  • RZV 在 IRD 患者中具有临床意义的保护效力与可接受安全性,推荐高风险成人接种两剂。
  • 接种后需短期监测 flare,尤其 SLE 患者,但不应因此避免接种。

研究设计与样本

  • 综述汇总 RZV 在 IRD 中的效力、效果、持久性与安全性证据及疫苗接种相关自身免疫 flare 新数据。
  • 证据包括随机对照试验、真实世界队列数据及 920 例自身免疫病患者的药物警戒分析。

主要发现

  • 随机对照试验显示 RZV 对稳定免疫抑制 IRD 成人短期 flare 风险非劣于安慰剂。
  • 真实世界队列数据显示接种后 HZ 复发约减少 95%,flare 极少且无严重疫苗相关事件。
  • 920 例自身免疫病患者药物警戒分析中 flare 发生率 8.5%,post-RZV flare 报告 OR 三倍升高,尤见于 SLE。

关键数值与推荐

  • EULAR、ACR、ACIP/CDC 及国家机构推荐 HZ 风险增高的 IRD 成人接种两剂 RZV,包括许多接受强效免疫抑制者。

临床怎么用

  • 对 HZ 风险增高的 IRD 成人(含强效免疫抑制者)按推荐接种两剂 RZV。
  • 接种后短期监测 flare,尤其 SLE 患者,并给予明确咨询而非回避接种。

局限性

  • 证据来自综述汇总,部分数据为真实世界与药物警戒分析,存在报告偏倚等局限。
  • 需进一步研究填补关键证据缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with inflammatory rheumatic diseases (IRDs) have a substantially increased risk of herpes zoster (HZ), driven by underlying immune dysregulation and immunosuppressive therapy, particularly high-dose glucocorticoids, biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors. The adjuvanted recombinant zoster vaccine (RZV) has shown high efficacy in preventing HZ in older adults and durable protection for at least 10 years. Emerging data in immunocompromised populations, including rheumatology cohorts, support clinically meaningful protection with an acceptable safety profile.Recent evidence includes randomised controlled trials demonstrating non-inferiority of RZV vs placebo for short-term flare risk in adults with IRDs on stable immunosuppression. Real-world cohort data also showed a marked reduction in HZ relapse after vaccination (approximately 95%), with very few flares and no serious vaccine-related events. In contrast, a pharmacovigilance analysis of 920 autoimmune patients identified an 8.5% flare incidence and a threefold increased reporting OR for post-RZV flares, particularly in systemic lupus erythematosus, underscoring the need for short-term monitoring and clear counselling rather than avoidance of vaccination.Updated recommendations from the European Alliance of Associations for Rheumatology, the American College of Rheumatology, the Advisory Committee on Immunisation Practices/Centers for Disease Control and Prevention and national bodies now support two doses of RZV for adults with IRD at increased HZ risk, including many receiving potent immunosuppression. This review summarises current evidence on the efficacy, effectiveness, durability and safety of RZV in IRD and interprets new data on vaccination-related autoimmune flares. It also proposes a practical vaccination strategy for rheumatology care and highlights key research gaps.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Krasselt M. Recombinant zoster vaccine in patients with inflammatory rheumatic diseases: efficacy, long-term protection and safety under immunosuppression. RMD Open. 2026. PMID: 42150841. doi:10.1136/rmdopen-2026-006994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。